Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert(Institut Gustave Roussy), Dirk Schadendorf(National Center for Tumor Diseases), Pascal Wolter(KU Leuven), Keith T. Flaherty(Cancer Research Center), Kamil Drucis(Apple (Israel)), Jacob Schachter, Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), M. Lichinitser(Apple (Israel)), Peng Sun(Philips (Finland)), Wendy Crist(Apple (Israel)), Axel Hauschild(University Hospital Schleswig-Holstein), Florent Grange(Hôpital Lyon Sud), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Laurent Mortier, Antoni Ribas(University of California, Los Angeles), Paul Nathan(Mount Vernon Hospital), Bogusława Karaszewska(State University of Applied Sciences in Konin), Reinhard Dummer(University Hospital of Zurich), Anne-Marie Martin(GlaxoSmithKline (United States)), D. Stroiakovski(Moscow City Oncology Hospital №62), Stephen D. Rubin(Pfizer (United States)), Ivana Krajsová(Charles University), Jeff Legos(Novartis (Switzerland)), Shonda M Little(Apple (Israel))
Cited by 2,679
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k